OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Risk assessment and careful planning are crucial for timely delivery
The rapid pace of drug development during the COVID-19 pandemic demonstrates the value of collaborations.
Innovators, contractors, and technology providers advance cell and gene therapies.
May 03, 2021
Breakthroughs in analytics and alternatives to traditional freeze drying promise to reshape biological development and the cold chain.
May 02, 2021
Mass spectrometry and automation are growing in importance for protein characterization, but further improvements are still needed.
April 23, 2021
Executives that participated in the CPhI post-pandemic survey are predicting a push for repatriation of manufacturing globally.
April 21, 2021
Post-inspection report reveals nine sanitary and process problems at Bayview, Md., facility.
April 09, 2021
Even before Emergent disclosed that it had to discard 15 million doses of the J&J vaccine drug substance, FDA inspectors had uncovered multiple deficiencies and quality control issues.
April 05, 2021
Following a manufacturing mix-up, J&J will extend its oversight at Emergent’s Maryland facility; AstraZeneca manufacturing to relocate.
April 03, 2021
Intensified and distributed manufacturing approaches create flexible, local capacity.
April 02, 2021
The availability of materials is a critical factor when it comes to vaccine capacity.
March 30, 2021
SGS is supporting Selecta Biosciences and Asklepios BioPharmaceutical with the Phase I dose-escalation trial of SEL-3999, an AAV8 vector capsid containing no transgene with ImmTOR.
Celonic will manufacture CvnCoV at its facility in Germany.